Switch theme
Sign up to access all valuation multiples
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
2021
493
Last FY Revenue $348M
Last FY EBITDA -$33.6M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Immunocore Holdings achieved revenue of $348M and an EBITDA of -$33.6M.
Immunocore Holdings expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Immunocore Holdings valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $348M | XXX | XXX | XXX |
| Gross Profit | XXX | $345M | XXX | XXX | XXX |
| Gross Margin | XXX | 99% | XXX | XXX | XXX |
| EBITDA | XXX | -$33.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -10% | XXX | XXX | XXX |
| EBIT | XXX | -$79.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | -23% | XXX | XXX | XXX |
| Net Profit | XXX | -$57.4M | XXX | XXX | XXX |
| Net Margin | XXX | -16% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Immunocore Holdings's stock price is EUR 31 (or $35).
Immunocore Holdings has current market cap of EUR 1.6B (or $1.8B), and EV of EUR 1.2B (or $1.4B).
See Immunocore Holdings trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.4B | $1.8B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Immunocore Holdings has market cap of $1.8B and EV of $1.4B.
Immunocore Holdings's trades at 3.9x EV/Revenue multiple, and -40.4x EV/EBITDA.
Equity research analysts estimate Immunocore Holdings's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Immunocore Holdings's P/E ratio is not available.
See valuation multiples for Immunocore Holdings and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 3.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -40.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -17.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -30.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 57.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialImmunocore Holdings's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.9M for the same period.
Immunocore Holdings's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Immunocore Holdings's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Immunocore Holdings and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -10% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 72% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 122% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Immunocore Holdings acquired XXX companies to date.
Last acquisition by Immunocore Holdings was XXXXXXXX, XXXXX XXXXX XXXXXX . Immunocore Holdings acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Immunocore Holdings founded? | Immunocore Holdings was founded in 2021. |
| Where is Immunocore Holdings headquartered? | Immunocore Holdings is headquartered in Germany. |
| How many employees does Immunocore Holdings have? | As of today, Immunocore Holdings has 493 employees. |
| Who is the CEO of Immunocore Holdings? | Immunocore Holdings's CEO is Dr. Bahija Jallal, PhD. |
| Is Immunocore Holdings publicy listed? | Yes, Immunocore Holdings is a public company listed on FRA. |
| What is the stock symbol of Immunocore Holdings? | Immunocore Holdings trades under 6YG ticker. |
| When did Immunocore Holdings go public? | Immunocore Holdings went public in 2021. |
| Who are competitors of Immunocore Holdings? | Similar companies to Immunocore Holdings include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Immunocore Holdings? | Immunocore Holdings's current market cap is $1.8B |
| Is Immunocore Holdings profitable? | Yes, Immunocore Holdings is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
